Tag Archives: Duloxetine

Pharmacological Treatment of Pain

While medications are often prescribed for all types of chronic pain, research has consistently shown that several classes have proven efficacy for the treatment of neuropathic pain. Ideally, pharmacotherapy of pain would be specifically selected on the basis of considerations of etiology (e.g., ischemic, neuropathic), pathophysiology (e.g., demyelination, central pain), and anatomy (e.g., C fibers,… Read More »

Selected Chronic Pain Conditions

Postherpetic Neuralgia Postherpetic neuralgia is defined as pain persisting or recurring at the site of shingles at least 3 months after the onset of the acute varicella zoster viral rash. Postherpetic neuralgia occurs in about 10% of patients with acute herpes zoster. More than half of patients over 65 years of age with shingles develop… Read More »

Minor Depression

Etiology and Pathophysiology Minor depression is only a proposed diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and there are no International Classification of Diseases codes to categorize it. The proposed diagnostic category for minor depression in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition describes a depressive disorder that… Read More »

Minor Depression: Duloxetine, Venlafaxine, and Milnacipran

Serotonin-Norepinephrine Reuptake Inhibitors Several antidepressants have dual action at both serotonergic and noradrenergic receptors. The most notable are the serotonin/norepinephrine reuptake inhibitors, particularly extended-release venlafaxine (Wyeth’s Effexor XR) and milnacipran (bioMerieux-Pierre Fabre’s Ixel/Dalcipran, Asahi Kasei/Janssen-Kyowa’s Toledomin; available only in France and Japan). The noradrenergic and specific serotonergic antidepressants (NaSSAs) mirtazapine (Organon’s Remeron/Remergil), nefazodone (Bristol-Myers Squibb’s… Read More »

Minor Depression: Serotonin-Norepinephrine Reuptake Inhibitors

Research and development efforts in depression are focusing on a wide variety of mechanisms; agents with the now-familiar mechanism of serotonin-norepinephrine reuptake inhibition make up only a small portion of development efforts. The most notable of these serotonin/norepinephrine reuptake inhibitors is Eli Lilly’s recently launched duloxetine. Duloxetine is the third serotonin/norepinephrine reuptake inhibitor to market,… Read More »

Chronic Illness: Emerging Therapies

Few new drugs are in clinical development for the treatment of Bipolar disorder. Most agents in clinical trials for this disorder (e.g., Bristol-Myers Squibb’s aripiprazole, Novartis’s oxcarbazepine, AstraZeneca’s quetiapine, Janssen’s risperidone, Ortho-McNeil’s topiramate, Pfizer’s ziprasidone) are already available in the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) for the treatment… Read More »

Major Depressive Disorder And Alzheimer’s Disease

Prevalence Major depressive disorders in Alzheimer’s disease are less common than depressive symptoms, although most studies have described increased rates compared to the general population. Published prevalence rates have a very large range, presumably because of sampling issues (clinical, convenience and population samples) as well as differing diagnostic schema. Because of this lack of consistency… Read More »

Pharmacotherapy of Treatment of Depression in Late Life

Antidepressant pharmacotherapy has become the cornerstone of management of depression in late life. Evidence from a number of meta-analyses documents convincingly that antidepressant medications are effective treatments of late-life depression. The newer medications were found to be as effective as tricyclic antidepressants () in these analyses, and generally are associated with fewer discontinuations due to… Read More »

Pharmacotherapy of Depressed Children and Adolescents

There have been relatively few pharmacokinetic and pharmacodynamic studies of antidepressants in children and adolescents, although metabolism usually takes place at similar or faster rates than in adults. While the ‘start low, go slow’ axiom is particularly appropriate here, children may ultimately require doses that are higher than usual adult doses on a mg/kg basis.… Read More »

Duloxetine 20 mg, 30 mg, 60 mg Capsules

Duloxetine (do-lox-e-teen) [Cymbalta] Duloxetine Classification (The therapeutic classification, which categorizes drugs by the disease state they are used to treat, appears first, followed by the pharmacologic classification, which is based on the drug’s mechanism of action.) Therapeutic class: antidepressants Pharmacologic class of Duloxetine: selective serotonin and norepinephrine reuptake inhibitors — SSNRIs Pregnancy Category (pregnancy categories… Read More »